Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
NVIDIA, Microsoft, and Amazon Eye Massive OpenAI Investment Amid $100B Funding Push 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
RA’ANANA, Israel and NEW YORK, May 30, 2017 -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Ron Bentsur, the Company’s Chief Executive Officer, will present at the Jefferies 2017 Global Healthcare Conference on Tuesday, June 6, 2017 at 1:30 p.m. EDT. The conference will be held in New York, NY.
A live audio webcast of the presentation will be available by visiting the Investors section of the UroGen Pharma website at http://investors.urogen.com. An archived replay of the webcast will be available on the Company's website for 90 days following the live presentation.
About UroGen Pharma Ltd.
UroGen Pharma (NASDAQ:URGN) is a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. The Company has developed RTGel, a proprietary sustained release, hydrogel-based formulation for potentially improving the efficacy and safety profiles of existing drugs. UroGen Pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen Pharma's lead product candidates, MitoGel and VesiGel, are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade UTUC and bladder cancer. UroGen Pharma is headquartered in Israel and also maintains a corporate office in New York City.
CONTACTS: UroGen Pharma Ltd. Gary Titus Chief Financial Officer [email protected] 646-768-9531 Or Burns McClellan, Inc. Steve Klass [email protected] 212-213-0006
